Introduction
As summarized in recent, comprehensive reviews, 1, 2 disorders of bone and joints provide several interesting opportunities for gene therapy. As most progress in the past 2 years has been made in the fields of arthritis and tissue regeneration, particularly as applied to bone, cartilaginous tissues, ligaments and tendons, these are the areas covered in this review.
Arthritis gene therapy: advances in preclinical studies
The concept of delivering cDNAs locally to joint tissues is well accepted as a therapeutic strategy, but until recently, it was not possible to achieve long-term transgene expression in joints. This is a concern, because most forms of arthritis are chronic conditions that will probably require prolonged transgene expression; in animal models, expression is typically lost within a few weeks. Studies by Gouze et al. 3 recently identified the host immune reaction as the major barrier to prolonged, transgene expression in the knee joints of rats. When recombinant lentivirus or adenovirus vectors carrying the hIL-1Ra (human interleukin-1 receptor antagonist) cDNA were injected into the knee joints of immunocompetent animals, hIL-1Ra expression was high initially, but lasted only for 3 weeks. When the same vectors were injected into the knee joints of athymic rats, transgene expression also decreased from an initially high level, but at 3 weeks reached a stable plateau of expression equal to B20% of peak levels. This persisted for at least 6 months without substantial further decline. These data suggest an early loss of transgene expression that did not require T-cell-dependent immunity, followed by delayed, T-cell-dependent loss. The latter was associated with the elimination of viral genomes and the preferential loss of CD90 + and CD29 + cells from the joints. When green fluorescent protein (GFP) cDNA was transferred to the knee joints of athymic rats, most of the GFP expression was found initially in the synovial lining. However, at day 168, GFP + cells had disappeared from the synovial lining, apart from the synovial fold adjacent to the cartilage; other GFP + cells were noted in fibrous tissues, including ligaments, tendons and the subsynovium (Figure 1 ).
Collectively, these data suggest that the delivery of cDNAs encoding homologous proteins with a vector that does not lead to the expression of viral proteins can support extended periods of stable transgene expression. Consistent with this conclusion, intra-articular expression of a rat soluble tumor necrosis factor receptor (sTNFR) transgene in immunocompetent rats persisted for at least 6 months when delivered by lentivirus. It is noted that persistent transgene expression did not require vector integration and was unaffected by the choice of promoter. These data are consistent with those of Sandalon et al. 4 who used AAV to deliver cDNA encoding rat bivalent sTNFR i.m. (intramuscularly) in rats. High levels of transgene expression, sufficient to suppress streptococcal cell-wall-induced arthritis, persisted for over a year presumably because the AAV vector does not encode viral proteins and was used to deliver an homologous protein to the rat. Although adenovirus was not tested in this study, using first-and second-generation adenovirus vectors would have presumably led to the expression of immunogenic viral proteins that curtail transgene expression. Gutted adenovirus vectors have the potential to obviate this restriction, but they have not yet been tested in joints. A large number of non-viral vectors have been screened, but none have been found able to Figure 1 Fibroblasts resident in fibrous articular tissues support stable expression of exogenous transgenes. After intra-articular injection of recombinant lentivirus or adenovirus vectors carrying green fluorescent protein (GFP) into the knees of nude rats, groups of animals were killed at days 5 and 168. The knee joints and surrounding tissues were harvested intact, decalcified and processed for histology. For each joint, the approximate positions of fluorescent cells identified in serial, sagittal whole-knee sections were tabulated in green on the knee joint diagrams similar to that shown on the left. The diagrams shown are representative of the results observed with both viruses at the respective times. On the right, images are shown characteristic of the appearance of the GFP+ cells in tissue sections at the different times ( Â 20 magnification). Lines indicate the approximate regions represented by the tissue sections. The numbers of GFP+ cells in the synovium and subsynovium were reduced dramatically at day 168. The density and distribution of GFP+ cells in the tendon, ligament and fibrous synovium were largely unchanged over the duration of the experiment. No fluorescent cells were seen in the articular cartilage with either virus at any time point. From Gouze et al.
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Further development of AAV vectors for human arthritis gene therapy Although, as described in the preceding section, several different vectors can be used to study arthritis gene therapy in experimental animals, recombinant AAV is emerging as the vector of choice for human application because it is perceived to be safe; no viral genes are expressed by transduced cells, and AAV can deliver cDNAs to the joints by direct, in vivo, intra-articular injection. Moreover, cDNAs encoding the cytokines and cytokine antagonists most commonly studied for use in arthritis are small enough for packaging in AAV vectors. On the basis of the experiments described above, AAV is expected to provide long-term transgene expression. Several groups are investigating the appropriate AAV serotype for use in joints. Serotype 5 appears to be the most effective in rats and mice, and a successful treatment of experimental arthritis in these animals has been reported using AAV5 carrying cDNAs encoding b-interferon 5 and sTNFRI-Ig. 6, 7 Boissier et al. 8 compared the abilities of AAV serotypes 1, 2, 5, and 8 to transduce human synovial fibroblasts in vitro, and determined an order of effectiveness of AAV2414548. However, when they examined human synovial fluids for neutralizing antibodies against these serotypes, they found a much stronger inhibition of AAV2 and AAV1 compared to that of AAV5 and AAV8. Thus, the authors suggested that although AAV5 transduced human synovial fibroblasts less efficiently than did AAV2 and AAV1, this serotype might be more efficient in clinical application because of reduced preexisting neutralizing immunity.
Recent studies aim to improve the efficiency of AAV in transducing synovial fibroblasts. Kay et al. 9 noted that self-complementing AAV2 was far more efficient than the equivalent single-stranded vector in transducing lapine synovial fibroblasts. Indeed, in vitro expression of a hIL-1Ra transgene was similar to that achieved previously with adenovirus and lentivirus vectors. After injection of the vector into normal or inflamed knee joints, hIL-1Ra was produced intra-articularly at therapeutic levels for 2 weeks; subsequent extinction of expression probably reflects an immune response to the hIL-1Ra by the host animal. Much interest had been sparked by reports in the older literature that transgene expression after delivery with AAV into the knee joints of rabbits and rats, although transient, could be reactivated by inflaming the joints. However, in the studies of Kay et al., 9 neither an inflammatory stimulus nor re-administration of vectors was able to restore transgene expression.
Tracking studies showed that, regardless of whether single-or double-stranded AAV was used, equivalent numbers of viral genomes entered the nuclei of synovial fibroblasts. This is consistent with the notion that lapine synovial fibroblasts do not undertake second strand synthesis very efficiently. These studies further showed that only 10-20% of the viral genomes that enter the cell translocate to the nucleus, an observation that identifies another constraint on transduction efficiency. Issues related to the use of AAV for gene transfer to joints are discussed in more detail in Ghivizzani et al. 10 
Further development of inducible promoters
As rheumatoid arthritis (RA) is a disease of flares and remissions, inducible promoters continue to be of interest. Those based on NF-kB (nuclear factor-kB) response elements, 6,7 the cyclooxygenase-2 promoter, 11 a hybrid interleukin-1 enhancer/interleukin-6 proximal promoter 12 and a doxycycline-dependent promoter 13 have recently been published. The last of these formed a part of a non-viral delivery strategy in which plasmids carrying a bivalent sTNFR were injected i.m. into mice, to inhibit arthritis in a doxycycline-dependent manner. The doxycycline-inducible system appeared to work well in this setting. Electroporation has also been used to enhance the intra-articular transfection efficiency of plasmids.
14 A number of additional transgenes have been tested recently for anti-arthritic activity in animal models. Those encoding IL-13, 15 modified prothymosin 16 and an IL-18-binding protein:IL-4 fusion protein 17 were effective, whereas IGF-1 18 was not. Unlike the other immunomodulatory products tested, IGF-1 was evaluated on the basis of its potential to protect and restore articular cartilage.
Use of RNAi (RNA interference)
The development of RNAi interference technologies has added a new dimension to the molecular treatment of arthritis. Khoury et al. 19 delivered siRNA directed against IL-1, IL-6 and IL-18 to mice with collageninduced arthritis intravenously. siRNA against each cytokine alone showed some efficacy, but knockdown of all three targets had the strongest anti-arthritic effect. Chen et al. used adenovirus to deliver siRNA directed against the p65 component of NF-kB into the knee joints of rats. This prevented activation of NF-kB in the synovium and cartilage, inhibited expression of IL-1 and TNF and slowed the progression of osteoarthritis (OA). 20 Facilitated local delivery of genes using cells that home to sites of disease As certain types of immune cells and, possibly, mesenchymal stem cells (MSCs) can home to sites of disease, they may be useful in what has been termed 'facilitated local gene therapy'.
1,2 Choi et al. 21 delivered IL-10 with a retrovirus to MSCs ex vivo which suppressed collagen-induced arthritis in mice after systemic injection. There is evidence that MSCs can be allografted, which provides a way to reduce the cost and complexity of ex vivo gene therapy. If confirmed, this is important, because the harvest, culture expansion under GMP conditions, genetic manipulation, testing and re-implantation of autologous cells is extremely expensive and limiting for clinical application. IL-10 cDNA was also successful in murine proteoglycan-induced arthritis when retrovirally transferred to CD4 + T cells selected for their ability to recognize proteoglycan. 22 Genetically modified dendritic cells have been shown previously to ameliorate murine models of arthritis. Kim et al. 23 recently reported the successful use of exosomes derived from dendritic cells transduced with IL-4. Exosomes are Genetic treatments for disorders of bones and joints CH Evans et al 50-90 nm vesicles released from many cell types. They hold several advantages over the use of the cells from which they were derived, including safety, efficacy and stability.
Arthritis clinical trials
Recently there have been three clinical trials for the gene therapy of RA and two for OA ( Table 1) . Two of these trials used a recombinant, single-stranded AAV2 vector carrying cDNA encoding a TNFR:Fc fusion protein (tgAAC94). 24 The recombinant protein, etanercept (Enbrel, Thousand Oaks, CA, USA), blocks the actions of TNF and is already used to treat RA by subcutaneous injection administered twice weekly.
In a Phase I study, tgAAC94 was injected intraarticularly into the joints of 14 subjects with RA and 1 with ankylosing spondylitis; 14 knee joints and 1 ankle were injected. Owing to the different volumes of the joints that could be injected in this study, doses were standardized as DNase-resistant particles (DRPs) per ml, with a standard volume of vector suspension injected into each type of joint. Four joints received placebo injections. Five joints received 10 10 DRP per ml and 6 received 10 11 DRP per ml. No drug-related adverse events were reported, but there was no measurable accumulation of transgene product in the synovial fluid. 24 A subsequent Phase II trial of tgAAC94 led to much controversy, because of the death of a study subject. 25 Unlike the Phase I study, the Phase II trial allowed repeated dosing and the inclusion of subjects who were already taking TNF antagonists, such as etanercept. The latter provision was based on the notion that joints for which disease was inadequately controlled by the systemic administration of recombinant protein might benefit from the additional TNF blockade provided by the local expression of etanercept.
The Phase II study involved 120 subjects, divided into 3 groups receiving 10 11 DRP per ml, 10 12 DRP per ml or 10 13 DRP per ml of tgAAC94. In each group, 30 subjects received tgAAC94 and 10 received placebo. Much publicity accompanied the death of a young woman, shortly after receiving a second injection of tgAAC94 into her right knee joint. The FDA placed the trial on hold but, following review, allowed the study to continue with minor modifications to the protocol. This complicated affair is described in great detail in Evans et al. 25 The trial has now been completed. Although the data have not been published as a full-length paper, preliminary reports suggest that some patients experienced symptomatic benefit. 26 In a third study that took place in Germany, IL-1Ra was introduced into the joints of two subjects with RA by an ex vivo protocol using autologous synovial fibroblasts transduced with a retrovirus. Although this study was small, preliminary and lacking in good outcome measurements, both subjects appeared to respond to the intra-articular transfer of IL-1Ra cDNA, one of them dramatically. 27 Two Phase I trials have recently begun for gene therapy of OA in the United States and in Korea. These make use of an established line of primary human articular chondrocytes, which have been retrovirally transduced with TGF-b 1 cDNA. So far, 12 subjects have been treated in Korea and 4 in the United States. No adverse events have been reported. This trial is unusual in using allogeneic cells, and the degree to which an allograft response might influence the outcome is a matter of some interest. Abbreviations: IL, interleukin; HSV-tk, Herpes simplex virus-thymidine kinase; NA, not applicable; N, number of subjects in study; OBA, Office of Biotechnology Activities; TNFR, tumor necrosis factor receptor. The Targeted Genetics trial can also recruit subjects with psoriatic arthritis and ankylosing spondylitis.
Modified from Evans et al. 25 with permission.
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Clinical trial for the aseptic loosening of prosthetic joints
Joints with advanced arthritis are often surgically replaced with a prosthesis. In B10% of cases, the lifetime of the artificial joint is limited by a process known as aseptic loosening during which the bone surrounding the implant is resorbed and replaced with periprosthetic fibrous tissue. Major surgery is necessary to replace the loosened prosthesis, and the replacement is often less successful than the original artificial joint. Moreover, many subjects needing revision surgery are poor candidates for surgery because of age and comorbidities. Huizinga's group (ref 28) have developed a genebased, non-surgical strategy for addressing aseptic loosening. It involves the intra-articular injection of a recombinant adenovirus that encodes nitrate reductase. The vector tracks to the fibrous tissue surrounding the loosened joint and transduces cells locally. The pro-drug, CB 1954, is then administered. Nitrate reductase converts this to its cytotoxic product that destroys the soft tissue around the implant. Liquid bone cement is then injected into the space thus created and solidifies in situ to resecure the prosthetic joint. It is interesting that preexisting neutralizing antibody to adenovirus 5 was an inclusion criterion on the basis that this limits the spread of infectious vector beyond the joint.
In a Phase I/II dose-escalation study, 12 subjects with aseptic loosening underwent this procedure. Improvements in walking distance, pain score and independence were noted at the highest two doses of 3 Â 10 10 and 10 11 adenovirus particles. 28 There were no adverse events related to the vector.
Strategies for gene-based tissue repair and regeneration
Four main strategies have emerged for treating damaged bone and joints with genes ( Figure 2 ). Two in vivo methods involve the direct injection of vector or the implantation of a GAM (gene-activated matrix). A GAM consists of a matrix, such as collagen, impregnated with a vector. After the GAM is implanted, it is infiltrated with local repair cells that engage the vector and express the transgene. Two ex vivo methods involve the ex vivo expansion of cells for genetic modification (traditional ex vivo) or the removal, modification and re-implantation of cells and tissues within a single operation (expedited ex vivo).
Advances in bone healing
Osteogenesis is very responsive to gene transfer, and the ability to trigger new bone formation in vivo through local delivery of a suitable cDNA is well established. Recent research focuses on determining which genes are the most appropriate and how best to deliver them. For clinical application, there is also an increasing appreciation of the need to develop technologies that allow this to be accomplished simply and inexpensively. 29 Although bone morphogenetic protein-2 (BMP-2) has been the most intensively studied transgene, there is increasing interest in evaluating additional BMPs and other growth factors. Bertone's group 30 noted the superiority of human BMP-2 over BMP-6 in healing osseous lesions in horses after the direct delivery of cDNA with recombinant, first-generation adenovirus vectors.
Although circulating antibodies against adenovirus were generated, it was not possible to detect viral genomes outside the site of application. Lu et al. 31 demonstrated the ability of a novel osteogenic protein, Nell-1, to produce spinal fusions in rats after direct adenoviral delivery of cDNA.
Because the biology of a fracture site evolves, Betz et al. 32 injected Ad.BMP-2 into an experimental rat segmental defect at different times after surgery. They noted a marked increase in repair when the administration of vector was delayed for 5-10 days. This may be associated with the formation of a stable hematoma within the defect, the influx of osteoprogenitor cells and the enhanced local expression of the coxsackie virus adenovirus receptor The same group also noted that the healing process in the model was dose-dependent with greater amounts of adenovirus leading to better bone healing, despite the increased potential for inflammatory responses to the adenovirus. 33 Using a different approach, Rundle et al. 34 accelerated the healing of a rat femoral fracture by the direct, intra-lesional injection of a retrovirus carrying cyclooxygenase-2 cDNA.
Ex vivo gene transfer is also commonly used for bone healing studies, especially when osteoprogenitor cells serve as the vehicles of gene delivery. Osterix, 35 and lim mineralization protein-3 36 cDNAs have recently been shown to be effective when delivered by the ex vivo route in various experimental models. These transgenes are well suited for gene transfer because they encode Genetic treatments for disorders of bones and joints CH Evans et al intracellular proteins that are otherwise difficult to administer. Ex vivo, adenoviral delivery of BMP-2 cDNA to osteoprogenitor cells derived from fat was used successfully for spinal fusion in rats. 37 Virk et al. 38 addressed the unresolved question of how long an osteogenic transgene should be expressed within a defect to produce an optimal healing response. They introduced a BMP-2 cDNA into rat femoral segmental defects by an ex vivo protocol involving marrow osteoprogenitor cells transduced with lentivirus or adenovirus vectors. These expressed the transgene in vivo for 8 weeks and less than 3 weeks, respectively. Although both vectors achieved osseous union, the new bone formed in response to lentiviral gene delivery had superior mechanical properties.
Most previous research in this area has focused on the use of growth factors, transcription factors and other molecules that induce osteogenesis. Recent work by Kwong et al. 39 indicates another approach that uses RNA knockdown of BMP antagonists, such as chordin, to promote bone healing.
Advances in the repair of cartilaginous tissues: articular cartilage, meniscus, intervertebral disc Unlike bone, cartilaginous tissues have almost no intrinsic repair capacity. A number of regenerative approaches involve the genetic modification of progenitor cells, which are subsequently implanted into the lesion.
Guo et al. 40 enhanced the repair of full-thickness lesions in rabbit articular cartilage using progenitor cells from the bone marrow, which were first expanded in culture, transfected with TGF-b 1 cDNA and seeded onto a chitosan scaffold. In a similar study, AAV was used to transfer TGF-b 1 cDNA into human MSCs, which were subsequently implanted into osteochondral defects in nude rats. 41 Healing was superior to that achieved with negative control GFP cDNA. It was noted that, by 12 weeks only 12% of the cells within the defect were GFP + . MSCs and meniscal cells transduced with TGF-b 1 cDNA were also shown to heal meniscal lesions in an in vitro model. 42 Gelse et al. 43 undertook an ambitious study in pigs. The large size of these animals allowed the creation of partial thickness cartilage defects in the patella. Defects were treated with autologous periosteal cells that had received BMP-2 cDNA, either by transfection of plasmid with liposomes, or transduction with a combination of adenovirus and AAV vectors. Control and transfected cells failed to regenerate new cartilage. By 6 weeks, defects receiving the transduced cells were filled with hyaline cartilage with the contact stiffness of native hyaline cartilage. However, by 6 months, the surface layers had started to form fibrocartilage with poor mechanical properties, although the deeper layers remained healthy. 43 Another large animal study was undertaken in the horse, in which cartilage lesions are a clinical problem and the transplantation of chondrocytes into defects is used therapeutically. The ex vivo transduction of chondrocytes before implantation with recombinant adenovirus carrying IGF-1 cDNA improved and accelerated healing. 44 Improvement was maintained for at least 8 months, unlike the case in an earlier study by the same group using BMP-7 cDNA.
Chondrogenesis can be studied in vitro using a pellet culture system that lends itself well to studying the effects of gene transfer. Earlier work with adenovirus vectors, confirmed that the transfer of TGF-b 1 cDNA triggered chondrogenic differentiation by marrow progenitor cells. IGF-1 cDNA did not promote differentiation, but enhanced matrix synthesis by chondrocytes. This suggested that co-transduction of both TGF-b 1 and IGF-1 should lead to the formation of larger amounts of cartilage, and this was recently shown to be the case. 45 Another form of combined genetic treatment uses IGF-1 cDNA to promote matrix synthesis by chondrocytes and IL-1Ra cDNA to prevent breakdown of the matrix in response to IL-1. A preliminary evaluation in a horse model provided promising results. 46 Degeneration of the intervertebral disc is another common clinical problem for which there is no nonsurgical solution. In vivo transduction of cells within the disc with the appropriate constructs promises to inhibit further breakdown of the matrix while stimulating repair. 47 As the disc is an isolated, alymphatic, avascular tissue, populated by non-dividing cells, prolonged periods of transgene expression are possible. Several recent papers provide additional insight into the appropriate choice of transgenes and vectors. Zhang et al. 48 compared the ability of cDNAs encoding 12 different BMPs or the transcription factor sox 9, associated with chondrogenesis, to promote matrix synthesis by annulus fibrosus cells when delivered by adenovirus. The same group went on to deliver BMP-7 and BMP-10 cDNAs to rabbit intervertebral discs in organ culture in an ex vivo manner using adenovirally transduced chondrocytes. The expression of BMP-7, but not of BMP-10, greatly enhanced proteoglycan synthesis. 49 To determine whether mixtures of growth factors would have synergistic effects, Moon et al. transferred cDNAs encoding IGF-1, TGF-b 1 and BMP-2, in various combinations, to human disc cells in alginate culture. The greatest increment in proteoglycan synthesis was obtained when all three growth factors were expressed. 50 Work by LeMaitre's group has established a key role for IL-1 in the matrix breakdown during human intervertebral disc degeneration. In recent studies, they have confirmed that the transfer of IL-1Ra cDNA to explants of human discs strongly inhibits matrix breakdown. 51 
Enhanced healing of ligaments and tendons
Attempts to enhance the repair of ligaments and tendons have focused on the transfer of cDNAs that either promote the differentiation of progenitor cells into ligamentocytes and tenocytes or enhance matrix synthesis by differentiated cells. The rat Achilles tendon transection model has been used to evaluate the effects of BMP-12 and BMP-14, two morphogens that enhance the differentiation of progenitor cells into tenocytes. Both studies used adenovirus for gene transfer by in vivo 52 or ex vivo 53 means. In both cases, healing was quicker and more complete in the presence of the transgene, leading to improved mechanical properties.
Clinically, it is common to use allografted ligaments and tendons for repair. As the processing of allografts kills endogenous cells, these grafts lack the viable cells necessary for repair. Schwarz's group have developed a method of allograft revitalization that has previously been shown to be effective with allografted bone. Their
Genetic treatments for disorders of bones and joints CH Evans et al method has recently been applied to the allografted tendon, with proof of principle shown recently in a mouse flexor tendon model. 54 The donor tendon was coated with AAV carrying growth and differentiation factor-5 (the murine equivalent of BMP-14). The coating process involved the freeze-drying of AAV onto the surface of the allograft. After implantation, the AAV became rehydrated and transduced cells surrounding the graft, leading to improved healing and reduced adhesions.
Ruptures of the anterior cruciate ligament can also be treated with allografts. Evaluating an alternative strategy for revitalizion, Li et al. 55 seeded genetically modified MSCs onto allografts before implanting them into a rabbit model. Addition of cells alone improved collagen deposition in the graft, whereas transfecting the cells with a plasmid containing PDGF-B cDNA additionally improved angiogenesis.
Another strategy for enhancing anterior cruciate ligament repair involves the in situ transfer of cDNAs to endogenous cells as they migrate from the ruptured ends of the ligament. Proof of principle has been shown previously using marker genes and TGF-b 1 cDNA delivered by adenovirus contained within a collagen hydrogel. Recent studies confirm the effectiveness of IGF-1 cDNA in this model. 56 
Prospects
Within the next 2 years, we should see publication of the data from the Phase I/II trial using tgAAC94 in subjects with RA. As well as providing possible efficacy data, it should provide information on a number of additional matters of importance to future trials, including the immune reaction to AAV after intra-articular delivery. During this time period, the results of the two gene therapy trials in OA should also become available. Collectively, these findings will be crucial to the further development of arthritis gene therapy, which is in pressing need of additional, well-designed clinical trials. 57 Phase I studies using AAV to deliver IL-1Ra are being developed for human and equine OA, but it is not known whether the sponsors of the tgAAC94 trials are planning further interventional studies in RA. It is also unknown whether there will be additional studies evaluating gene therapy for the treatment of aseptic loosening.
There continues to be high activity in the use of gene transfer technologies to solve problems in the healing of bone and cartilage, and it is encouraging that investigators are beginning to report promising results in the large animal models that are required before human use can be contemplated. It cannot be predicted which strategy will emerge as the leader, but technologies that avoid ex vivo cell culture, such as those based on GAMs, including allograft revitalization, have advantages of cost and simplicity. However, it is unlikely that any of these will be in human clinical trials within 2 years. Preclinical studies will continue to focus on the evaluation of different transgenes as agents of repair, and the selection of the appropriate gene delivery methods for eventual clinical use. Most research uses rodents to provide experimental models, and more research in large animal models is required. We can expect to see more use of RNAi technologies, as this area continues its rapid growth.
